Online citations, reference lists, and bibliographies.

Availability And Approval Of Cannabis‐based Medicines For Chronic Pain Management And Palliative/supportive Care In Europe: A Survey Of The Status In The Chapters Of The European Pain Federation

N. Krčevski-Škvarč, C. Wells, W. Häuser
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
There is considerable public and political interest in the use of cannabis products for medical purposes.
This paper references
10.1002/ejp.1118
Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews
W. Häuser (2018)
Kannabistako kipul€ a€ akkeksi? Suomen L€ a€ ak€ arilehti 71
E Kalso (2016)
10.5041/RMMJ.10239
Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders
J. Ablin (2016)
10.1016/j.drugalcdep.2015.11.015
Trends in registered medical marijuana participation across 13 US states and District of Columbia.
B. Fairman (2016)
10.1186/s12954-016-0129-7
Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey
Des Crowley (2017)
10.1056/NEJMra1402309
Adverse health effects of marijuana use.
N. Volkow (2014)
10.1016/j.jpain.2015.07.014
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
M. Ware (2015)
Medical use of cannabis products : Lessons to be learned from Israel and Canada
J. N. Ablin
Medical cannabis . Number of applications increases [ German ]
K. Gießelmann (2017)
10.1159/000444236
Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years
F. Patti (2016)
10.1007/s00482-015-0089-y
[Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
F. Petzke (2016)
10.1186/1471-2474-15-258
Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints
Mary-Ann Fitzcharles (2014)
10.1007/s00482-015-0083-4
Medical use of cannabis products
J. Ablin (2015)
10.1016/j.annemergmed.2019.07.034
[MEDICAL CANNABIS].
T. Naftali (2016)
10.15252/embr.201439742
Medicinal use of cannabis in Europe
M. Bifulco (2015)
Cannabis for medical use: a scientific review.
L. Dillon (2017)
Medical cannabis Physicians against cannabis flowers
P B€ Uhring (2016)
10.1097/AJP.0000000000000364
The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study
S. Haroutounian (2016)
Cannabis for medical use
Health Products Regulatory Agency (2017)
Medical cannabis. German Pain Society welcomes the enactment of the federal government
10.1007/s11926-016-0625-5
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
Mary-Ann Fitzcharles (2016)
Main principles of Cannabis policy for medical use
Ministry of Health (2016)
10.1503/cmaj.109-5129
Growing the evidence base for medical cannabis
S. Lough (2015)
Guideline on clinical medicinal products intended for the treatment of neuropathic pain
European Medicines Agency (2007)



This paper is referenced by
10.1007/s11469-019-00152-8
Medical Cannabis Pain Benefit, Risk and Effectiveness Perceptions Among Belarus Medical Students
N. Khamenka (2019)
10.1007/s00482-019-0383-1
[Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].
Patric Bialas (2019)
10.1080/1744666X.2019.1665997
Medical cannabis and cannabinoids in rheumatology: where are we now?
P. Sarzi-Puttini (2019)
10.18004/rvspmi/2312-3893/2018.05(02)12-018
Cannabis in chronic pain - An indication supported by scientific evidence?
Manuel Benítez Codas (2018)
10.1007/s00482-019-00397-1
Cannabispräparate für die Therapie chronischer Schmerzen
Marc Heidbreder (2019)
10.5114/pm.2018.77198
Cannabinoids – the possible use in palliative medicine
T. Dzierżanowski (2018)
10.1159/000505027
Development of a Vaping Machine for the Sampling of THC and CBD Aerosols Generated by Two Portable Dry Herb Cannabis Vaporisers
L. Carrara (2020)
10.1186/s13741-019-0127-x
Cannabis-based medicines and the perioperative physician
Patrick Tapley (2019)
10.1007/s00482-019-0373-3
Efficacy, tolerability and safety of cannabis-based medicines for cancer pain
W. Häuser (2019)
10.1007/s40674-019-00130-0
Cannabis-Based Medicines and Medical Cannabis in Rheumatic Diseases: A Treasure Chest or Pandora’s box
Mary-Ann Fitzcharles (2019)
10.15416/pcpr.v3i3.19979
Should Cannabis as Medicine be Specifically Regulated
Gunawan Widjaja (2018)
10.1007/s00482-019-0383-1
Cannabispräparate bei chronischen Schmerzen: Indikationen, Präparateauswahl, Wirksamkeit und Sicherheit
Patric Bialas (2019)
10.1007/s00406-018-0960-9
Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain
G. Campbell (2018)
10.1016/j.euroneuro.2020.04.009
Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion
Erwin Krediet (2020)
10.3390/ijerph16173095
International Perspectives on the Implications of Cannabis Legalization: A Systematic Review & Thematic Analysis
A. Bahji (2019)
10.1007/s00482-019-00403-6
Erratum zu: Cannabispräparate bei chronischen Schmerzen: Indikationen, Präparateauswahl, Wirksamkeit und Sicherheit
P. Bialas (2019)
10.1159/000505028
An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?
A. Schlag (2020)
10.1016/j.bcp.2018.07.033
Chronic pain and cannabinoids. Great expectations or a christmas carol
D. Pascual (2018)
10.1007/s00482-019-00409-0
Medizinalcannabis und cannabisbasierte Arzneimittel: ein Appell an Ärzte, Journalisten, Krankenkassen und Politiker für einen verantwortungsvollen Umgang
Winfried Häuser (2019)
10.1136/rapm-2020-101521
Daring discourse – yes: practical considerations for cannabis use in the perioperative setting
H. Clarke (2020)
10.1007/978-3-319-90365-1_6
The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders
David R Janero (2019)
10.3389/fneur.2018.00731
Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey
K. A. Klotz (2018)
10.1016/j.jns.2020.116717
Clinical uses of cannabis and cannabinoids in the United States
Erik A. Levinsohn (2020)
10.1002/acr2.11138
Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada
Mary-Ann Fitzcharles (2020)
10.1002/14651858.CD012182.pub2
Cannabis-based medicines for chronic neuropathic pain in adults.
M. Muecke (2018)
10.1016/J.RHUM.2019.03.009
Le cannabis dans les douleurs musculosquelettiques et articulaires : des preuves sont nécessaires
Serge Perrot (2019)
10.1007/s00103-019-02966-2
Evidenz der Wirksamkeit und Sicherheit von Cannabispräparaten bei chronischen Schmerzen
Winfried Häuser (2019)
10.1007/s00482-019-00407-2
Ein Positionspapier zu medizinischem Cannabis und cannabisbasierten Medikamenten in der Schmerzmedizin
F. Petzke (2019)
10.1016/j.bmcl.2019.03.013
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
Yedukondalu Nalli (2019)
10.14740/jocmr4210
A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults
Reham Haleem (2020)
10.1002/ejp.1297
European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain management
W. Häuser (2018)
10.3390/cancers11020129
Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence
T. Dzierżanowski (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar